Empaglifl ozin: from controlling glycemia to reducing cardiovascular death in patients with type 2 diabetes. New data

Turmuhambetova Balslu Nurmuradova

the article presents the results of the use of empagliflozin in patients with type 2 diabetes mellitus (DM). The effect of this drug on the effectiveness of glycemic control, blood pressure (BP), blood lipid spectrum, body weight was analyzed, and compliance was assessed. Own experience of using empagliflozin as part of combined hypoglycemic therapy indicates that the drug is easy to use, helps to achieve sufficient glycemic control (significant reduction in glycated hemoglobin by an average of 0.98%), reduces body weight in the presence of obesity or overweight (decrease in body mass index by an average of 1.78 kg/m2), has a positive effect on blood PRESSURE, does not significantly affect the correction of dyslipidemia in the presence of transient adverse reactions in individual women in the form of cystitis and vulvovaginitis, do not require discontinuation of treatment. The use of empagliflozin in the complex hypoglycemic therapy of patients with type 2 diabetes is advisable to achieve compensation [3].

Keywords:type 2 diabetes mellitus, empagliflozin, research, cardiovascular insufficiency, efficacy, safety, clinical practice